Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Norge - norsk - myHealthbox

bayer ag -

Norge - norsk - Ecolab

ecolab deutschland gmbh -

Norge - norsk - Statens legemiddelverk

mylan ab - metoprololtartrat - tablett - 50 mg

Norge - norsk - Statens legemiddelverk

n.v. organon - kloosterstraat - mometasonfuroat - inhalasjonspulver - 200 mikrog

Norge - norsk - Statens legemiddelverk

n.v. organon - kloosterstraat - mometasonfuroat - inhalasjonspulver - 400 mikrog

Norge - norsk - Statens legemiddelverk

teva sweden ab - beklometasondipropionat - inhalasjonsaerosol, oppløsning - 50 mikrog/ dose

Norge - norsk - Statens legemiddelverk

teva sweden ab - beklometasondipropionat - inhalasjonsaerosol, oppløsning - 100 mikrog/ dose

Norge - norsk - Statens legemiddelverk

teva sweden ab - beklometasondipropionat - inhalasjonsaerosol, oppløsning - 50 mikrog/ dose

Norge - norsk - Statens legemiddelverk

teva sweden ab - beklometasondipropionat - inhalasjonsaerosol, oppløsning - 100 mikrog/ dose